Pluristem Issues Letter to Shareholders Highlighting Milestones

Pluristem Therapeutics

today announced that the Company has issued a letter to shareholders that provides an overview of the numerous milestones recently achieved by the company. The letter can be found on the company's website. Highlights include: Raised net $34 million in a secondary offering, bringing the company's cash position to approximately $70 million, with no debt   Targeting future clinical trials in Bone Marrow Transplant failure indications, following the improvement of clinical condition and hematological counts after treatment of critically ill patients under a compassionate use program at the Hadassah Medical Center in Jerusalem   Began FDA-approved Phase II clinical trials in the U.S. for Intermittent Claudication   Received approval for Phase I/II clinical trial in muscle injury in Germany   Received approval from the Indian Ministry of Health to begin Phase II clinical trials in Buerger's Disease patients   Filed for Orphan Drug Status with the U.S. FDA for Aplastic Anemia   Optimizing manufacturing processes for commercial scale up   Building a new state-of-the-art manufacturing GMP facility in Israel suitable for large-scale production.   Pursuing new indications and fields of research in lung disease and acute radiation syndrome